Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/54105
Title: Different fatty acid metabolism effects of (−)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer
Author: Relat Pardo, Joana
Blancafort, Adriana
Oliveras Serrat, Glòria
Cufí, Sílvia
Haro Bautista, Diego
Marrero González, Pedro F.
Puig i Miquel, Teresa
Keywords: Càncer de pulmó
Àcids grassos
Metabolisme
Aprimament
Lung cancer
Fatty acids
Metabolism
Weight loss
Issue Date: 6-Jul-2012
Publisher: BioMed Central
Abstract: Background Fatty acid synthase (FASN) is overexpressed and hyperactivated in several human carcinomas, including lung cancer. We characterize and compare the anti-cancer effects of the FASN inhibitors C75 and (−)-epigallocatechin-3-gallate (EGCG) in a lung cancer model. Methods We evaluated in vitro the effects of C75 and EGCG on fatty acid metabolism (FASN and CPT enzymes), cellular proliferation, apoptosis and cell signaling (EGFR, ERK1/2, AKT and mTOR) in human A549 lung carcinoma cells. In vivo, we evaluated their anti-tumour activity and their effect on body weight in a mice model of human adenocarcinoma xenograft. Results C75 and EGCG had comparable effects in blocking FASN activity (96,9% and 89,3% of inhibition, respectively). In contrast, EGCG had either no significant effect in CPT activity, the rate-limiting enzyme of fatty acid β-oxidation, while C75 stimulated CPT up to 130%. Treating lung cancer cells with EGCG or C75 induced apoptosis and affected EGFR-signaling. While EGCG abolished p-EGFR, p-AKT, p-ERK1/2 and p-mTOR, C75 was less active in decreasing the levels of EGFR and p-AKT. In vivo, EGCG and C75 blocked the growth of lung cancer xenografts but C75 treatment, not EGCG, caused a marked animal weight loss. Conclusions In lung cancer, inhibition of FASN using EGCG can be achieved without parallel stimulation of fatty acid oxidation and this effect is related mainly to EGFR signaling pathway. EGCG reduce the growth of adenocarcinoma human lung cancer xenografts without inducing body weight loss. Taken together, EGCG may be a candidate for future pre-clinical development.
It is part of: BMC Cancer, 2012, vol. 12, num. 280
Related resource: http://dx.doi.org/10.1186/1471-2407-12-280
URI: http://hdl.handle.net/2445/54105
ISSN: 1471-2407
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Files in This Item:
File Description SizeFormat 
614971.pdf523.36 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons